Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Hamish Ryder"'
Autor:
Maria Antonia Buil, Manuel Fuentes Ferrer, Sonia Espinosa, Francisca Antón, Jordi Castro, Josep M. Huerta, Jorge Beleta, Manuel López, Mònica Córdoba, Dolors Vilella, Montserrat Miralpeix, Gaspar Casals, Maria Prat, Victor Segarra, Maria Dolors Fernández, Hamish Ryder, Marisa González, Alvaro Cardenas, Juan Manuel Monleón, Israel Ramos, Laia Tort, Amadeu Gavaldà
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:1736-1741
Novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides have been identified as potent M3 muscarinic antagonists with a long duration of action in an in vivo model of bronchoconstriction. The synthesis, structure-activity relationships and
Autor:
Susanne Müller, David M. Andrews, Anne Cheasty, Hamish Ryder, Paul V. Fish, Tim C. P. Somervaille, Catherine Rogers, Neil P. Jones, Cynthia Tallant, Niall Igoe, Gauri Deb, Dafydd R. Owen, Paul Brennan, Pavel Savitsky, Oleg Fedorov, Elliott D. Bayle, Stefan Knapp
The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Evaluation of the BRPF family as a potential drug target is at an early stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501396c7182bc9411ab90cf51e60d306
https://doi.org/10.1021/acs.jmedchem.6b01583
https://doi.org/10.1021/acs.jmedchem.6b01583
Autor:
Mar Jimenez Quesada, Ellen Catherine Macdonald, Allan M. Jordan, Caroline Foxton, Huib Ovaa, Pritom Shah, Elisabeth Trivier, Aurore Lejeune, Tony Raynham, Wouter H. Moolenaar, Muddasar Farooq, Martin Stockley, P.J. Owen, James R. Hitchin, Jana Skeete, Michelle Pritchard, Irene Farre Gutierrez, Hamish Ryder, Niall M. Hamilton, Andrew P. Turnbull, Anne Cheasty, Leon Pang, Alexandra Stowell, Susan M. Boyd
Publikováno v:
Bioorganic and Medicinal Chemistry Letters, 26(22), 5403-5410
The autotaxin-lysophosphatidic acid (ATX-LPA) axis has been implicated in several disease conditions including inflammation, fibrosis and cancer. This makes ATX an attractive drug target and its inhibition may lead to useful therapeutic agents. Throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7b70a8962d8c311e0ac46deffdc0f8
https://hdl.handle.net/1887/111844
https://hdl.handle.net/1887/111844
Autor:
Mireia Gómez-Angelats, Jordi Gras, Dolors Vilella, Amadeu Gavaldà, Marisa Viñals, Montserrat Miralpeix, Jorge Beleta, Esteban J. Morcillo, Hamish Ryder, Raquel Otal, Israel Ramos, Julio Cortijo, Jorge De Alba, Carla Carcasona, Carlos Puig, Mònica Aparici
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 342:497-509
Abediterol is a novel potent, long-acting inhaled β(2)-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Abediterol shows subnanomolar affinity for the human β(2)-adrenoceptor and a functiona
Autor:
Mònica Córdoba, Amadeu Gavaldà, Montserrat Miralpeix, Jordi Serrat, Elena Calama, Lluís Pagès, Jorge Beleta, Joan Taltavull, Jose Luis Montero, Miriam Andrés, Hamish Ryder, Dolors Vilella, Begoña Hernández, Jordi Gràcia
Publikováno v:
European Journal of Medicinal Chemistry. 46:4946-4956
A series of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidines (PFP) were synthesized and tested for phosphodiesterase type 4 (PDE4) inhibitory activity, with the potential to treat asthma and chronic obstructive pulmonary disease (COPD). Structure–activi
Autor:
Jordi Serrat, Jordi Gràcia, Montserrat Miralpeix, Joan Taltavull, Lluís Pagès, Amadeu Gavaldà, Mònica Córdoba, Hamish Ryder, Miriam Andrés, Dolors Vilella, Jorge Beleta
Publikováno v:
Journal of Medicinal Chemistry. 53:6912-6922
A series of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines (PTP) has been synthesized and tested as phosphodiesterase IV inhibitors (PDE4), a target for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Structure-activity relations
Autor:
Joan Albertí, Manuel Fuentes Ferrer, Sonia Sentellas, María I. Crespo, Hamish Ryder, Amadeu Gavaldà, Jorge Beleta, Israel Ramos, M. Antonia Buil, Sonia Espinosa, Manuel López, Jordi Castro, Maria Prat, Francisca Antón, Josep M. Huerta, Dolors Fernández, Marisa González, Gaspar Casals, Dolors Vilella, Teresa Doménech, Victor Segarra, Montserrat Miralpeix, Alvaro Cardenas, Juan Manuel Monleón, Laia Tort
Publikováno v:
Journal of Medicinal Chemistry. 52:5076-5092
The objective of this work was to discover a novel, long-acting muscarinic M3 antagonist for the inhaled treatment of chronic obstructive pulmonary disease (COPD), with a potentially improved risk−benefit profile compared with current antimuscarini
Autor:
Carles Puig, Jordi Bach, Laia Sole, Hamish Ryder, Daniel I. Pérez, Jordi Sanahuja, Alfredo Gonzalez
Publikováno v:
Tetrahedron Letters. 50:2750-2753
A practical and efficient three-step sequence for the deamination of α-aminoesters is reported. This method is based on the NaBH4-mediated selective reduction of α-diazoesters to α-hydrazonoesters and has been successfully applied to the deaminati
Autor:
Alvaro Cardenas, María Isabel Cadavid, Cristina Esteve, Bernat Vidal, Jose Luis Diaz, Estrella Lozoya, Arsenio Nueda, Jorge Beleta, María Isabel Loza, Hamish Ryder
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:3642-3645
A new series of 4-(1,3-dialkyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)benzenesulfonamides has been identified as potent A2B adenosine receptor antagonists. The products have been evaluated for their binding affinities for the hu
Autor:
Carles Puig, Jordi Gras, Elena Calaf, Arantxa Cardús, Lluís Pagès, Jorge Beleta, Montse Miralpeix, Francisca Antón, Graham Warrellow, Hamish Ryder, José Prieto, Alvaro Cardenas, Mònica Aparici, Silvia Fonquerna, Josep M. Huerta, Dolors Vilella
Publikováno v:
Journal of Medicinal Chemistry. 47:6326-6337
A series of indolylpiperidinyl derivatives were prepared and evaluated for their activity as histamine H(1) antagonists. Structure-activity relationship studies were directed toward improving in vivo activity and pharmacokinetic profile of our first